

Resource Summary Report

Generated by [RRID](#) on Aug 10, 2026

Anti-KLRG1-APC, human

RRID:AB_2652574

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-103-639, RRID:AB_2652574

Antibody Information

URL: http://antibodyregistry.org/AB_2652574

Proper Citation: Miltenyi Biotec Cat# 130-103-639, RRID:AB_2652574

Target Antigen: KLRG1

Host Organism: human

Clonality: monoclonal

Comments: Discontinued: 12-2017; Target Distribution basophils, T cells, NK cells; target type Non-CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-117-703. (RRID:AB_2733432).

Antibody Name: Anti-KLRG1-APC, human

Description: This monoclonal targets KLRG1

Target Organism: human

Clone ID: REA261

Antibody ID: AB_2652574

Vendor: Miltenyi Biotec

Catalog Number: 130-103-639

Record Creation Time: 20250819T225206+0000

Record Last Update: 20250820T033342+0000

Ratings and Alerts

No rating or validation information has been found for Anti-KLRG1-APC, human.

Warning: Discontinued: 2021

Discontinued: 12-2017; Target Distribution basophils, T cells, NK cells; target type Non-CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-117-703. (RRID:AB_2733432).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Ciancaglini C, et al. (2026) Protocol to isolate, expand, and activate human type 2 innate lymphoid cells to study immune checkpoint function. STAR protocols, 7(2), 104461.

Chen L, et al. (2018) CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. Immunity, 49(3), 464.